Digi.Bio

The company uses single-cell, AI-driven lab-on-a-chip technology to analyze individual cell behavior and identify the most effective drug candidates.

NecstGen, a non-profit contract development and manufacturing organization (CDMO) for cell and gene therapies, partners with Digi.Bio to advance testing in cell therapy development. Digi.Bio provides lab-on-a-chip technology to streamline and improve efficiency in therapeutic testing processes. The collaboration aims to accelerate innovation in cell and gene therapy research.

Feb 2025NecstGenNews article

MassChallenge Switzerland selects its 6th cohort of startups for acceleration. Digi.Bio, a Netherlands-based company, joins the program. The initiative supports early-stage ventures across Europe with mentorship, funding, and networking opportunities.

May 2021MassChallengeNews article

Digi.Bio and SwissDeCode are collaborating to develop a platform for automated milk fraud detection. The system combines a hardware device with embedded software, funded by the EUREKA-Eurostars program. This partnership aims to streamline fraud identification in the dairy industry.

Jul 2020StartupReporter.euNews article

Dutch digital biology firm **Digi.Bio** and Swiss DNA detection company **SwissDeCode** have partnered to develop an automated platform for detecting milk fraud. The collaboration aims to streamline fraud identification in dairy supply chains using advanced biological testing methods.

Jul 2020DairyReporter.comNews article